Seeking Alpha

Threshold Pharmaceuticals (THLD -5.4%) succumbs to profit taking, after bouncing back strong...

Threshold Pharmaceuticals (THLD -5.4%) succumbs to profit taking, after bouncing back strong from Monday's selloff over poor clinical trial results for its hypoxia-targeted drug TH-302. Separately, Maxim initiated coverage on the stock today with a Buy, saying that TH-302 is currently in a phase III trial as a first-line treatment with doxorubicin for advanced soft tissue sarcoma as well, and there's a good chance for a significant improvement in overall survival.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|